Glenmark shares drop as MSD takes it to Court

Posted By:
Subscribe to GoodReturns

Shares in domestic pharma company Glenmark dropped after report's that Merck's Indian unit, MSD, has filed a case against the company in the Delhi High Court for infringement of intellectual property rights.

The shares of the company were last trading at Rs 483, after touching a low of Rs 479 in trade today.

Most of the domestic pharma stocks continued to rally in trade following a Supreme Court verdict against MNC pharma company Novartis.

Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity) with five molecules in various stages of clinical development.

The company has a significant presence in branded generics markets across emerging economies including India. Its subsidiary, Glenmark Generics Limited has a fast growing and robust US generics business.

The subsidiary also markets APIs to regulated and semi-regulated countries. Glenmark employs over 10,000 people in over 80 countries. It has thirteen manufacturing facilities in four countries and has five R&D centres.

Read more about: glenmark
Please Wait while comments are loading...
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'

Thousands of Goodreturn readers receive our evening newsletter.
Have you subscribed?